Fig. 1: Fpn is downregulated in the hippocampus of AD mice and patient brain tissues.
From: Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease
A Representive protein level of Fpn in the hippocampus of APPswe/PS1dE9 (APP/PS1) mice at different ages (M: month) and the age-matched wild-type littermates (WT). B The quantification for protein level of Fpn in the hippocampus of APPswe/PS1dE9 (APP/PS1) mice (n = 3). C Immuno-histochemistry of Fpn and the DAB-enhanced Perl’s Prussian blue iron staining in the hippocampus of APPswe/PS1dE9 (APP/PS1) mice and the age-matched wild-type littermates (WT) at 9 months old. D The protein level of Fpn in brain tissues of AD patients and control (CON) sample (frontal cortex, 3 con vs 4 AD). E The fold change of the quantification for the protein level of Fpn in cortical brain tissues of AD patients (n = 10) compared to corresponding control (CON) samples (n = 9). F Correlation analysis between the Fpn protein level (Log2FC: The log2 fold-change of the Fpn protein expression level compared to the average of the controls) and the MMSE scores of subjects. The corresponding serial numbers of the human samples are marked with red number adjacent to each point (n = 14). Protein expression levels were detected by western blotting. Data are shown as the mean ± SD of at least three independent experiments. Statistical analyses were carried out using two-way ANOVA and mutiple t-test. *p < 0.05; **p < 0.01; ***p < 0.001. Detailed Statistical analyses are included with the Supplementary Table S4.
